Table 3.

ADHD treatment utilization and patterns

	France		Germany		Italy		Netherlands		Spain		UK		Total (Europe)
	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Total number of patients (N)	130		151		144		74		134		146		779
Lines of treatment
One	85	65.4	77	51.0	81	56.3	46	62.2	69	51.5	64	43.8	386	49.6
Two	37	28.5	45	29.8	60	41.7	19	25.7	48	35.8	55	37.7	295	37.9
Three	7	5.4	24	15.9	3	2.1	7	9.5	15	11.2	17	11.6	73	9.4
Four	1	0.8	3	2.0	0	0.0	1	1.4	1	0.8	7	4.8	18	2.3
Five or more	0	0.0	2	1.3	0	0.0	1	1.4	1	0.8	3	2.1	7	0.90
Current treatment typea
No treatmentb	12	9.2	14	9.37	9	6.3	2	2.7	2	1.5	7	4.8	46	5.9
Pharmacotherapy only	71	54.2	84	55.6	33	22.9	45	60.8	48	35.8	93	63.7	374	48.0
BT only	10	7.7	10	6.6	59	41.0	1	1.4	9	6.7	1	0.9	90	11.6
Pharmacotherapy and BT	37	28.5	43	28.5	43	29.9	26	35.1	75	56.0	45	30.8	269	34.5
Current treatment classc, d
Short-acting MPH	39	34.2	56	36.8	43	54.4	25	31.7	0	0.0	16	10.2	179	25.1
Long-acting MPHe	73	64.0	82	54.0	0	0.0	45	57.0	91	68.9	107	68.2	398	55.8
Short-acting AMP	0	0.0	1	0.76	7	8.9	1	1.3	0	0.0	2	1.3	11	1.5
Atomoxetinef	1	0.9	13	8.6	29	36.7	8	10.1	13	9.9	32	20.4	96	13.5
Others	1	0.9	0	0.0	0	0.0	0	0.0	28	21.2	0	0.0	29	4.1

N total number of patients, BT behavioural therapy, MPH methylphenidate, AMP amphetamine

^aPercentages are based on the total number of patients reporting treatment type

^bNot included in any analyses

^cPercentages are based on the total number of patients reporting treatment class

^dTreatment could be monotherapy or combination therapy

^eLong-acting MPH is not approved for use in Italy

^fAtomoxetine is not approved for use in France